Your browser doesn't support javascript.
loading
Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series.
Bravi, Carlo A; Fossati, Nicola; Gandaglia, Giorgio; Suardi, Nazareno; Mazzone, Elio; Robesti, Daniele; Osmonov, Daniar; Juenemann, Klaus-Peter; Boeri, Luca; Jeffrey Karnes, R; Kretschmer, Alexander; Buchner, Alexander; Stief, Christian; Hiester, Andreas; Nini, Alessandro; Albers, Peter; Devos, Gaëtan; Joniau, Steven; Van Poppel, Hendrik; Shariat, Shahrokh F; Heidenreich, Axel; Pfister, David; Tilki, Derya; Graefen, Markus; Gill, Inderbir S; Mottrie, Alexander; Karakiewicz, Pierre I; Montorsi, Francesco; Briganti, Alberto.
Afiliação
  • Bravi CA; Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: bravi.carloandrea@hsr.it.
  • Fossati N; Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Gandaglia G; Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Suardi N; Department of Urology, Policlinico San Martino Hospital, University of Genova, Genova, Italy.
  • Mazzone E; Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Robesti D; Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Osmonov D; Department of Urology and Pediatric Urology, University Hospital Schleswig Holstein, Campus Kiel, Germany.
  • Juenemann KP; Department of Urology and Pediatric Urology, University Hospital Schleswig Holstein, Campus Kiel, Germany.
  • Boeri L; Department of Urology, Mayo Clinic, Rochester, MN, USA; Department of Urology, IRCCS Foundation Ca Granda, Maggiore Policlinico Hospital, University of Milan, Milan, Italy.
  • Jeffrey Karnes R; Department of Urology, Mayo Clinic, Rochester, MN, USA.
  • Kretschmer A; Department of Urology, Ludwig-Maximilians University, Munich, Germany.
  • Buchner A; Department of Urology, Ludwig-Maximilians University, Munich, Germany.
  • Stief C; Department of Urology, Ludwig-Maximilians University, Munich, Germany.
  • Hiester A; Department of Urology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
  • Nini A; Department of Urology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany; Department of Urology and Pediatric Urology, Saarland University Medical Center, Saarland University, Homburg, Germany.
  • Albers P; Department of Urology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
  • Devos G; Department of Urology, University Hospitals Leuven, Leuven, Belgium.
  • Joniau S; Department of Urology, University Hospitals Leuven, Leuven, Belgium.
  • Van Poppel H; Department of Urology, University Hospitals Leuven, Leuven, Belgium.
  • Shariat SF; Department of Urology, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
  • Heidenreich A; University of Cologne, Department of Urology, Cologne, Germany.
  • Pfister D; University of Cologne, Department of Urology, Cologne, Germany.
  • Tilki D; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Graefen M; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Gill IS; USC Institute of Urology, University of Southern California, Los Angeles, CA, USA.
  • Mottrie A; Department of Urology, OLV Ziekenhuis Aalst, Melle, Belgium.
  • Karakiewicz PI; Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, QC, Canada.
  • Montorsi F; Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Briganti A; Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Eur Urol ; 78(6): 779-782, 2020 12.
Article em En | MEDLINE | ID: mdl-32624281
The best surgical template for salvage pelvic lymph node dissection (sLND) in patients with nodal recurrence from prostate cancer (PCa) after radical prostatectomy (RP) is currently unknown. We analyzed data of 189 patients with a unilateral positive positron emission tomography (PET) scan of the pelvic lymph node areas, who were treated with bilateral pelvic sLND after RP at 11 high-volume centers. The primary endpoint was missed contralateral disease at final pathology, defined as lymph node positive for PCa in the side opposite to the positive spot(s) at the PET scan. Overall, 93 (49%) and 96 (51%) patients received a 11C-choline and a 68Ga prostate-specific membrane antigen (PSMA) PET scan, respectively, and 171 (90%) and 18 (10%) men had one and two positive spots, respectively. The rate of missed contralateral PCa was 18% (34/189), with the rates being 17% (29/171) and 28% (5/18) in men with one and two positive spots, respectively. While the rate of contralateral disease did not differ between 68Ga-PSMA and 11C-choline (29% and 27%, respectively) among men with two positive spots, the rate of contralateral PCa was only 6% with 68Ga-PSMA versus 28% with 11C-choline in patients with a single positive spot. This finding was confirmed at multivariable logistic regression analysis predicting missed disease at final pathology after accounting for confounders (odds ratio: 0.24; p = 0.001). However, in men with a single positive spot at 68Ga-PSMA PET/computed tomography, the rate of single confirmed lymph node metastasis at final pathology was only 33%, suggesting the need for extended template even if unilateral dissection is performed. Awaiting confirmatory studies, patients diagnosed with a single positive spot at the 68Ga-PSMA PET scan might be considered for unilateral extended pelvic sLND. PATIENT SUMMARY: We assessed the risk of missing contralateral disease in patients with a positron emission tomography (PET) scan suggestive of unilateral nodal recurrence from prostate cancer (PCa) after radical prostatectomy and who were treated with bilateral salvage lymph node dissection (sLND). Variability exists according to the number of positive spots and PET tracer, with the lowest rate of missed PCa in men diagnosed with a single positive spot at a 68Ga prostate-specific membrane antigen PET scan (6%). If replicated, our data suggest that these patients might be considered for unilateral extended pelvic sLND.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prostatectomia / Neoplasias da Próstata / Terapia de Salvação / Excisão de Linfonodo / Metástase Linfática / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans / Male Idioma: En Revista: Eur Urol Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prostatectomia / Neoplasias da Próstata / Terapia de Salvação / Excisão de Linfonodo / Metástase Linfática / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans / Male Idioma: En Revista: Eur Urol Ano de publicação: 2020 Tipo de documento: Article